Eli Lilly | Passifs Courants



Current Liabilities Changement Date
AbbVie USD 36.4B 2.35B 2025-03
Abbott USD 13.44B 435M 2025-06
ALKERMES USD 505.96M 62.23M 2025-06
Amgen USD 20.48B 2.53B 2025-06
AstraZeneca USD 33.54B 4.41B 2025-06
Baxter International USD 3.48B 3.03B 2025-03
Biogen USD 3.18B 2.11B 2025-06
Bristol-Myers Squibb USD 27.53B 3.46B 2025-06
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 39.02B 8.95B 2025-06
Gilead Sciences USD 11.19B 1.15B 2025-06
GlaxoSmithKline GBP 20.38B 453M 2025-06
Glaxosmithkline GBP 21.7B 238M 2024-12
J&J USD 56.9B 6.58B 2025-03
Medtronic USD 12.88B 1.04B 2025-04
Merck USD 26.04B 863M 2025-06
Neurocrine Biosciences USD 546.3M 23.4M 2025-06
Novartis USD 31.71B 95M 2025-06
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 207.52B 28.6B 2025-06
Perrigo USD 1.13B 52.3M 2025-06
Pfizer USD 37.73B 1.27B 2025-06
Prestige Brands USD 109.67M 3.04M 2025-06
Regeneron Pharmaceuticals USD 3.67B 100.4M 2025-06
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 29.06B 3.16B 2025-06
Sanofi 29.16B 865M 2024-12
United Therapeutics USD 527.1M 194.4M 2025-06
Zoetis USD 3.37B 19M 2025-06


Eli Lilly Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.